InvestorsHub Logo
Followers 88
Posts 8196
Boards Moderated 0
Alias Born 06/17/2013

Re: Bb81 post# 54021

Friday, 10/07/2022 3:42:35 PM

Friday, October 07, 2022 3:42:35 PM

Post# of 65720
The ApoptoCyte procedure was developed during experiments with the JadiCell™ mesenchymal stem cell which the Company has licensed for used in Lung Pathology, Chronic Traumatic Encephalopathy (CTE), and Traumatic Brain Injury (TBI). The FDA has cleared a Phase III clinical trial for the JadiCell product in lung failure due to Covid-19. Use of the JadiCell for CTE is subject of a filed IND #27377 for which the Company is in the process of responding to FDA questions.

March 07, 2022

https://www.businesswire.com/news/home/20220307005467/en/Therapeutic-Solutions-International-Announces-ApoptoCyte-Procedure-for-Enhancing-Stem-Cell-Activity
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TSOI News